Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2
Barbro Selander, … , Lennart Truedsson, Anders G. Sjöholm
Barbro Selander, … , Lennart Truedsson, Anders G. Sjöholm
Published May 1, 2006
Citation Information: J Clin Invest. 2006;116(5):1425-1434. https://doi.org/10.1172/JCI25982.
View: Text | PDF
Research Article Immunology

Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2

  • Text
  • PDF
Abstract

Lectin pathway activation of C3 is known to involve target recognition by mannan-binding lectin (MBL) or ficolins and generation of classical pathway C3 convertase via cleavage of C4 and C2 by MBL-associated serine protease 2 (MASP-2). We investigated C3 activation in C2-deficient human sera and in sera with other defined defects of complement to assess other mechanisms through which MBL might recruit complement. The capacity of serum to support C3 deposition was examined by ELISA using microtiter plates coated with O antigen–specific oligosaccharides derived from Salmonella typhimurium, S. thompson, and S. enteritidis corresponding to serogroups B, C, and D (BO, CO, and DO). MBL bound to CO, but not to BO and DO, and efficiently supported C3 deposition in the absence of C2, C4, or MASP-2. The existence of an MBL-dependent C2 bypass mechanism for alternative pathway–mediated C3 activation was clearly demonstrated using CO, solid-phase mannan, and E. coli LPS. MASP-1 might contribute, but was not required for C3 deposition in the model used. Independent of MBL, specific antibodies to CO supported C3 deposition through classical and alternative pathways. MBL-dependent C2 bypass activation could be particularly important in various inherited and acquired complement deficiency states.

Authors

Barbro Selander, Ulla Mårtensson, Andrej Weintraub, Eva Holmström, Misao Matsushita, Steffen Thiel, Jens C. Jensenius, Lennart Truedsson, Anders G. Sjöholm

×

Figure 8

MBL-dependent C2 bypass activation by solid-phase mannan (A) and mannan-rich E. coli O8 LPS (B).

Options: View larger image (or click on image) Download as PowerPoint

                  MBL-dependent C2 bypass activation by solid-phase man...
The LPS was also used after partial delipidation (C). The LPS coating dose was 0.01 mg/well. rMBL at 4 mg/l was added to C2D:21 serum (combined C2 and MBL deficiency). The experiments were performed using 25% serum in VBS, VBS-Mg2+EGTA, and VBS-EDTA (see Methods). Mean values of at least 3 experiments are shown together with SEM for experiments with VBS.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts